The synthesis and antibacterial activity of sodium (3S,42Q-3-[2-(2-aminothiazol-4-yl)-(Z)-2-(0-substituted oxyimino)acetamido]-2-azetidinone-l -sulfonates having various substituted ethyl groups at the C-4 position are described. Amongvarious substituents explored, the (substituted isothiuronio)ethyl groups were found to have strong antibacterial activity against a variety of Gram-negative bacteria, and moreover, the ethylene isothiuronium derivative exhibited moderate antibacterial activitv aeainst Stavhvlococcus aureus.
The synthesis and antibacterial activity of sodium (3S,42Q-3-[2-(2-aminothiazol-4-yl)-(Z)-2-(0-substituted oxyimino)acetamido]-2-azetidinone-l -sulfonates having various substituted ethyl groups at the C-4 position are described. Amongvarious substituents explored, the (substituted isothiuronio)ethyl groups were found to have strong antibacterial activity against a variety of Gram-negative bacteria, and moreover, the ethylene isothiuronium derivative exhibited moderate antibacterial activitv aeainst Stavhvlococcus aureus.
In our previous paper, we reported on the synthesis and antibacterial activity of sodium (3S,4R)-3- [2-(2-aminothiazol-4-yl) -(Z )-2-( 0-substituted oxyimino)acetami do]-4-(2-methoxyethyl)-2-azetidinone-1-sulfonates (1)°. It has been shown that these compounds have strong antibacterial activity against a variety of Gram-negative bacteria and excellent stability against /3-lactamases. However, they showed weak activity against Pseudomonas aeruginosa. With the view of further improvement of the antibacterial activity against P. aeruginosa, wesynthesized a numberof l-sulfo-2-azetidinones having various kinds of substituents at the C-4 position.
In this paper, the synthesis and antibacterial activity of 4-(2-substituted ethyl)-2-azetidinone-1-sulfonic acid derivatives (2) are described. Chemi stry
The synthesis of the 4-(2-hydroxyethyl) compounds (5A1}~5C), the key intermediates for various 4-(substituted ethyl)-2-azetidinones, is shown in Scheme 1. Protection of the 7-amino group of (6i^7S)-7-amino-2,2-dimethyl-3-oxa-l -azabicyclo [4.2.0] octan-8-one (3)°gave 7-benzyloxycarbonylamino and 7-phthalimido derivatives 
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(4AX) and 4B), which were treated with HC1 in methanol to provide (4i?)-4-(2-hydroxyethyl)-2-azetidinones (5A1} and 5B), respectively. 3-Acylammo-4-(2-hydroxyethyl)-2-azetidinone (5C) was similarly prepared by acylation of 3 followed by removal of the acetonide.
1718 THE JOURNAL OF ANTIBIOTICS DEC. 1987 Various 3,4-c/.s-4-(2-substituted ethyl)-2-azetidinone derivatives (8 and 9) were prepared from (5A and 5B) by converting the hydroxy group into various substituents (Scheme 2). Tosylation of 5A and 5B afforded 4-tosyloxyethyl compounds (6A and 6B), which were subsequently converted into 4-(2-chloroethyl) and 4-(2-iodoethyl) derivatives (8a-A and 8b-B), respectively. Then, compound 8b-B was treated with thiols followed by silylation with terf-butyldimethylchlorosilane to give the 4-(2-substituted thioethyl) derivatives (9c-B and 9d-B). On the other hand, O-and iV-disilylation of 5A and 5B followed by regioselective desilylation with HC1 in cold methanol gave the iV-silylated alcohols (7A and 7B), respectively.
The 4-(2-carbamoyloxyethyl) derivative (8e-A) was prepared by treating 7A with trichloroacetyl isocyanate followed by desilylation with tetra-fl-butylammonium fluoride. The 4-(2-phenoxyethyl) derivatives (9f-B~9h-B) were obtained by the Mitsunobu reaction^of 7B and phenols.
Deprotection of 8A and 9B followed by acylation with the mixed anhydride of 2-(2-chloroaceta-
acid3) and^?-toluenesulfonyl chloride, followed by desilylation in the case of JV-silylated compounds (10), afforded the 3-acylamino compounds (ll). The 4-(2-acyloxyethyl) derivatives (Hi and llj) were synthesized by treating 5C with acetyl chloride and chloroacetyl chloride, respectively. Then, sulfonation of these compounds (ll) with sulfur trioxide Scheme 3. pyridine complex (SO3 -Py) gave the l-sulfo-2-azetidinone derivatives (12), which were subsequently converted into sodium 3 -[2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-4-(2-substituted ethyl)-2-azetidinone-l-sulfonates (13) by removing the chloroacetyl group of 12 with sodium N-methyldithiocarbamate3). derivative (131) was similarly prepared from 5C by sulfonation and subsequent deprotection procedure (Scheme 3).
Moreover, various 4-(2-substituted ethyl)-l-sulfo-2-azetidinones (18 and 20) were prepared from 4-iodoethyl derivatives (16A, 19A and 19B) by nucleophilic displacement (Scheme 4). Deprotection of 5A and subsequent acylation with 2-(2-triphenylmethylaminothiazol-4-yl)-(Z)-2-(0-substituted oxyimino)acetic acid4) and dicyclohexylcarbodiimide in the presence of 1-hydroxybenzotriazole gave 3-acylamino-4-(2-hydroxyethyl)-2-azetidinones (14A and 14B). Mesylation of 14A and 14B gave the 4-(2-mesyloxyethyl) compounds (15A and 15B), which were then transformed into the 4-(2-iodoethyl) derivatives (16A and 16B). 16A was treated with sodium azide, potassium cyanide and morpholine to give 17a, 17b and 17c, respectively. Then, 17a was hydrogenated and subsequently acylated with acetyl chloride and benzoyl chloride to give the 4-(2-acylaminoethyl) derivatives (17d and 17e). Sulfonation of 17 with SO3 Py and subsequent deprotection of triphenylmethyl group with 80% acetic acid, followed by treating with NaHCO3in the case of 17a, 17b, 17d and 17e, gave the deprotected products (18). On the other hand, sulfonation and subsequent deprotection of the triphenylmethyl group of 16A and 16B gave the sulfonates (19A and 19B) , which were treated with thioureas and pyridine, followed by removal of the tert-butyl group with HCOOH in the case of 19B, to give the various 4-(2-isothiuronioethyl) and 4-[2-(l-pyridinio)ethyl] compounds (20A and 20C). The MIC values of the 4-(2-substituted ethyl)-l-sulfo-2-azetidinones (13, 18 and 20) against S. aureus and a variety of Gram-negative bacteria were determined by the agar dilution method. Aztreonam5)was used as a reference compound. and 20). Most of these compounds showed good antibacterial activity against Gram-negative bacteria except P. aeruginosa. Amongvarious 4-substituents tested, 4-(2-carbamoyloxyethyl), 4-(2-azidoethyl) and 4-(2-isothiuronioethyl) groups were found to be efficient substituents for the antibacterial activity.
Antibacterial Activity and Conclusions
Especially, the 4-(2-isothiuronioethyl) derivative (20f-A) showed strong antibacterial activity against Table 1 . Antibacterial activity of compounds 13, 18, 19 and 20 (MIC (^g/ml) 
Compound
: a variety of Gram-negative bacteria. In general, as the lipophilicity of the 4-substituent increased, the compoundsshowed less activity against Gram-negative bacteria. Especially, introduction of an aromatic ring as a part of the substituent significantly decreased the activity against Gram-negative bacteria (13f, 13g, 13h and 18e). However, 131 showed only weak activity in spite of high hydrophilicity. These results agreed with those obtained for C-4-(substituted methyl) monobactams6~8). As the isothiuronioethyl group was the most efficient substituent, various 4-(2-substituted isothiuronioethyl)-l-sulfo-2-azetidinones (20) were synthesized.
The biological results are shown in Table 2 . These isothiuronium derivatives showed excellent antibacterial activity. iV-Monomethylation of the amino group of thiourea resulted in an increase of the antibacterial activity, but N,N'-dimethylation decreased the activity (compare 20g-A and 20h-A). Moreover, interestingly, Nalkylated isothiuronium derivatives having the methoxyimino group as a part of the 3-acyl moiety (20g~20i-A and 20J-A) showed not only good antibacterial activity against Gram-negative bacteria but also moderate activity against Gram-positive bacteria, S. aureus. On the other hand, replacement of the methoxyiminogroup by the carboxymethoxyiminogroup resulted in an increase of the activity against Gram-negative bacteria, as expected. The iV-methylisothiuronium derivative (20g-C) was more active than the corresponding 4-(2-methoxyethyl) compound as previously reported1}, and
showed nearly the same high activity as aztreonam. However, these isothiuronium derivatives were less active than aztreonam only against P. aeruginosa. Despite the great efforts to introduce various substituents at the C-4 position, no compounds were found to have really sufficient activity against P. aeruginosa. However,we have found compounds having moderate activity against S. aureus as well as excellent activity against a variety of Gram-negative bacteria except P. aeruginosa.
Experimenta l
Melting points were measuredon a Yanagimotomelting point apparatus and are uncorrected. Optical rotations were determined using a Jasco DIP-140 digital polarimeter. IR spectra were obtained on a Jasco IRA-1 or Hitachi 270-30 spectrometer. XHNMRspectra were recorded on a Hitachi R-20A (60 MHz) or a Hitachi R-90H (90 MHz) spectrometer using TMS or 3-(trimethylsilyl)-propionic acid sodium salt (TSP) as an internal standard. Secondary ion mass spectra (SI-MS) were measured on a Hitachi M-80Bmass spectrometer. Silica gel (Wakogel C 200) was used for column chromatography.
In Vitro Antibacterial Activity MICs were determined by the standard 2-fold agar dilution method9) using Mueller-Hinton agar (Difco) after 18 hours at 37°C with an inoculum size of 106 cfu/ml. (6.56 g, 30 mmol) and triethylamine (NEt3) (3.04 g, 30 mmol) were added to a solution of 31} (3.40 g, 20 mmol) in DMF(50 ml), and the mixture was stirred overnight at room temp. After further addition of Nefkens' reagent and NEt3 (each 10 mmol), stirring was continued for 24 hours at room temp. The solvent was removed under reduced pressure, and the residue was dissolved in CHC13 (100 ml) and brine (50 ml). The separated organic layer was dried and concentrated under reduced pressure. Ether was added to the residue to give 4-B* (4.55 
(135 mg, 1 mmol) and dicyclohexylcarbodiimide (206 mg, 1 mmol) in DMF(5 ml) was stirred overnight at 0~5°C. The precipitate was filtered off, and the filtrate was concentrated under reduced pressure. The residue was dissolved in EtOAc (20 ml) and washed successively with satd NaHCO3and brine, dried and concentrated under reduced pressure.
The residue was crystallized from MeOH-ether -hexane to give 4-C* (360 mg, 83%) as colorless crystals. MP 180-190°C (dec).
(3 5,4i?)-3 -Phthalimido-4-(2-hydroxyethyl)-2-azetidinone (5-B) Compound5-B* was synthesized from 4-B by a similar method to that described in preparation
2 n HC1 (2.5 ml) was added to a solution of4-C (470mg, 1.07 mmol) in MeOH(10ml), and the mixture was stirred for 8 hours at room temp. The resulting precipitate was collected by filtration and washed with MeOHand water to give 5-C* (338 mg, 81 %) as a colorless powder.
(5-A) (1.19 g, 4.5 mmol) was added to a solution ofi?-toluenesulfonyl chloride (1.7 g, 9 mmol) in pyridine (10 ml) at 0~5°C. After being stirred for 3 hours at the same temp, the reaction mixture was poured into EtOAc(50 ml) and ice-water (50 ml) and adjusted to pH 2 with 1 n HC1. Conventional work-up of the organic layer followed by crystallization from benzene -hexane afforded 6-A* (1.46 g, 77 %) as colorless crystals.
MP 124~125°C.
(36' ,4i?)-3 -Phthalimido-4-(2-^-toluenesulfonyloxyethyl)-2-azetidinone (6-B) Compound6-B* was prepared from 5-B by a similar method to that described in preparation of 6-A. Yield 92%. Colorless crystals.
MP 93-94°C.
(3 5>,4i?)-3 -Phthalimido-4-(2-hydroxyethyl)-l -/gr^-butyldimethylsilyl-2-azetidinone (7-B) Compound 7-B* was synthesized from 5-B by a similar method to that described in preparation of 7-A1}. Yield 75%. Colorless crystals. MP 142-143°C.
(3 5,4i?)-3-Benzyloxycarbonylamino-4-(2-chloroethyl)-2-azetidinone (8a-A) A mixture of 6-A (800 mg, 1.9 mmol) and lithium chloride (640 mg, 15 mmol) in Me2CO(20 ml) was refluxed for 5 hours, and the solvent was evaporated to dryness. The residue was dissolved in CH2C12(50 ml) and brine (25 ml), and the separated organic layer was washed successively with 10% sodium thiosulfate and brine, dried and concentrated under reduced pressure. The residue was washed with ether to give 8a-A* (502 mg, 93%) as colorless crystals. MP 171-173°C.
Compound 8b-B* was synthesized from 6-B and sodium iodide by a similar method to that described in preparation of 8a-A. Pale yellow crystals. Yield 90%. MP204~207°C (dec).
(3 5,4i?)-3 -Benzyloxycarbonylamino-4-(2-carbamoyloxyethyl)-2-azetidinone (8e-A) Trichloroacetyl isocyanate (207 mg, 1.1 mmol) was added dropwise to a solution of (3*S,4i?)-3-benzyloxycarbonylamino-4-(2-hydroxyethyl)-l-^r/-butyldimethylsilyl-2-azetidinone (7-A)1} (378 mg, 1 mmol) in CH2C12(5 ml) at 0~5°C. After being stirred for 2 hours at room temp, tetra-^-butylammoniumfluoride-XH2O (400 mg) was added, and the reaction mixture was stirred for 1 hour at room temp. To this solution was added silica gel (10 g). After 1 hour at room temp, the mixture was chromatographed on silica gel (CH2C12 -MeOH,10 : 1) to give 8e-A* (270 mg, 88%) as colorless crystals. MP 196-197°C. THE JOURNAL OF ANTIBIOTICS DEC. 1987 (3^4i?) -3 -Phthalimido-4-(2-ethylthioethyl)4^g^butyldimethylsilyl-2-azetidinone (9c-B) Ethyl mercaptan (250 mg, 4 mmol) was added to a solution of potassium hydroxide (123 nig, 2.2 mmol) in MeOH(5 ml). After being stirred for 30 minutes at 0~5°C, a solution of8b-B (740 mg, 2 mmol) in DMF(5 ml) was added, and the resultant mixture was stirred for 30 minutes at the same temp. After being stirred overnight at room temp, AcOH(0.1 ml) was added to the reaction mixture. The solvent was removed under reduced pressure, and the residue was dissolved in DMF(20 ml). After adding ter/-butyldimethylchlorosilane (600 mg, 4 mmol) and NEt3 (400 mg, 4 mmol) at 0-5°C, the mixture was stirred overnight at room temp, and diluted with ether (100 ml) and brine (50 ml). Conventional work-up of the separated organic layer followed by chromatography on silica gel (etherhexane, 1 : 1) gave 9c-B* (615 mg, 73%) as colorless crystals. MP 99~100°C.
(3ff, 4i?)-3-Phthalimido-442-(l -met idinone (9d-B)
Compound 9d-B* was similarly synthesized described above by treating 8b-B with sodium 1-methyl-l£T-tetrazolyl-5-thiolate (prepared from 1 -methyl-l#-tetrazolyl-5-thiol and sodium hydride in
To a mixture of 7-B (374 mg, 1 mmol), triphenylphosphine (315 mg, 1.2 mmol) and phenol (282 mg, 3 mmol) in anhydrous THF (10 ml) was added diethyl azodicarboxylate (209 mg, 1.2 mmol) at 0~5°C under nitrogen, and the mixture was stirred for 1 hour at the same temp. After removing the solvent, the residue was chromatographed on silica gel (ether -hexane, 1 : 1) to give 9f-B* (245 mg, 54%) as colorless crystals. MP111-112°C.
Compounds 9g-B and 9h-B were similarly prepared. acid (180 mg, 0.64 mmol),^-toluenesulfonyl chloride (124 mg, 0.65 mmol) and NEt3 (65 mg, 0.64 mmol) in CH2C12 (3 ml) was stirred for 50 minutes at 0-5°C. On the other hand, a mixture of8a-A (90mg, 0.32mmol), 1 n HC1 (0.35 ml) and 5% Pd-C (30mg) in MeOH(5 ml) was stirred for 2 hours at room temp under a hydrogen atmosphere, and the catalyst was filtered off. The filtrate was concentrated under reduced pressure, and the residue was dissolved in CH2C12(5 ml) containing NEt3 (65 mg, 0.64 mmol). This solution was added in one portion into the mixed anhydride solution prepared above, and the mixture was stirred for 2 hours at room temp. The resulting precipitate was collected by filtration and washed successively with CH2C12,water and MeOHto give lla (115 mg, 87%) as a colorless powder.
Compoundlie was prepared from 8e-A by a similar method to that described above. Results are shown in Table  3 . Method B: Procedure staring from 9-B; (a) a mixture of 9c-B (259 mg, 0.6 mmol) and methylhydrazine (276 mg, 6 mmol) in CH2C12(10 ml) was stirred for 1 hour at room temp, and the reaction mixture was subjected to chromatography on silica gel (CH2C12-MeOH, 20 : 1) to remove excess methylhydrazine. The eluent was concentrated under reduced pressure, and the residue was dissolved in CHC13(10 ml) and the mixture was stirred for 2 days at room temp. The resulting precipitate was filtered off, and the filtrate was concentrated to give the 3-amino compound (170 mg), which was acylated by a similar method to that described in preparation of lla to afford 10c (170 mg, 54%) as a colorless powder. Compounds lOd, lOf, lOg and lOh were similarly prepared described above. These compounds gave satisfactory physical data.
(b) To a solution of 10c (105mg, 0.2mmol) in MeOH(2ml) was added 1 n HC1 (0.4ml), and the mixture was stirred for 6 hours at room temp. The resulting precipitate was filtered off and washed Yield from 8-A; b yield from 9-B; c yield from 5-C. 3.75 (3H, s, OCH3), m, m, 5.13 (1H, dd, /=5.5, 9, 6.72 (1H, s, 7.12 (2H, br s, NH2), 7.48 (1H, d, J=9, aromatic H), 8.46 (1H, dd, /=3, 9, aromatic H), 8.73 (1H, d, /=3, aromatic H), 9.32 (1H,  3.76 (2H, t, /=6.5, s, OCH3), m, 5.41 (1H, d, J=5.5, 6 .99 (1H, s, thiazole-5H) (D2O); m, 4.00 (3H, s, OCH3), 4.19 (2H, t, /=6.5, m, 5.35 (1H, d, 7.00 (1H, s, a (M+Na)+ and (M+H)+ peaks were not observed. THE JOURNAL OF ANTIBIOTICS DEC. 1987 with MeOHand ether to give lie (65 mg, 74%) as a colorless powder.
Compounds lid, llf, llg and llh were similarly prepared and the results are shown in Table 3 . Method C: Procedure starting from 5-C; to an ice-cold solution of 5-C (100 mg, 0.26 mmol) in DMF(5 ml) were added pyridine (31 mg, 0.39 mmol) and acetyl chloride (47 mg, 0.6 mmol), and the mixture was stirred for 1 hour at 0~5°C. After being stirred for 30 minutes at room temp, the solvent was evaporated to dryness. The residue was dissolved in EtOAc (10 ml) and cold 1 n HC1 (5 ml), and the organic layer was washed with brine, dried and concentrated under reduced pressure. The residue was washed with EtOAc to give Hi (90 mg, 80%) as a colorless powder.
Compoundllj was similarly prepared by treating 5-C with chloroacetyl chloride. The result is shown in Table 3 . (12) A mixture of lla (90 mg, 0.22 mmol) and SO3 Py (70 mg, 0.44 mmol) in DMF (2 ml) and CH2C12 (2 ml) was stirred for 3 hours at 50°C. The solvent was evaporated under reduced pressure, and the residue was chromatographed on silica gel (CHC13 -MeOH-H2O, 100:30:5). The eluent was concentrated, and the residue was dissolved in water (3 ml) and treated with Dowex 50W (Na+) for 1 hour at room temp. After removal of the resin by filtration, the filtrate was lyophilized to give lla (95 mg, 84 %), which was used in the next reaction without further purification.
Compounds12c~12j and 1 were similarly prepared and the results are shown in Table 4 .
To an ice-cooled solution of 12a (61 mg, 0.12 mmol) in water (2 ml) was added sodium iV-methyldithiocarbamate (20 mg, 0.15 mmol) and stirred for 90 minutes at room temp. The mixture was diluted with water (5 ml) and washed with ether. The aqueous solution was chromatographed on Diaion HP-20. Elution with water and 10% EtOH, followed by lyophilization, gave 13a (45 mg, 86 %) as a colorless powder.
13c~13i, 13k and 131 were similarly prepared and the results are shown in Table 5 .
Compound 5-A (1.85 g, 7 mmol) was hydrogenated in MeOH(20 ml) for 5 hours over 5% Pd-C (100 mg) at room temp under a hydrogen atmosphere. The catalyst was filtered off and the filtrate was concentrated to dryness. The resulting crystals were treated with 2-(2-triphenylmethylaminothiazol-4-yl)-(Z)-2-methoxyiminoacetic acid (3.41 g, 7.7 mmol)4), 1-hydroxybenzotriazole (0.95 g, 7 mmol) and dicyclohexylcarbodiimide (1.45 g, 7 mmol) according to the similar method in preparation of 4-C to give 14-A* (3.31 g, 85%) as a colorless powder. 
